Reuters -- AstraZeneca’s once-daily cancer pill Iressa has been approved for certain lung cancer patients in Europe, reviving the fortunes of a product that had until recently been largely written off by industry analysts.
Reuters -- AstraZeneca’s once-daily cancer pill Iressa has been approved for certain lung cancer patients in Europe, reviving the fortunes of a product that had until recently been largely written off by industry analysts.
